Ketamine + Dexmedetomidine

Ketamine combined with dexmedetomidine represents a well-established injectable anesthetic protocol for reptiles that leverages the complementary mechanisms of these two agents to produce reliable chemical restraint and surgical anesthesia. Ketamine is a dissociative anesthetic that produces a cataleptic state through antagonism of N-methyl-D-aspartate receptors in the central nervous system, while dexmedetomidine is a highly selective alpha-2 adrenergic agonist that provides sedation, analgesia, and muscle relaxation through activation of inhibitory presynaptic receptors. The combination addresses limitations of ketamine alone, particularly the lack of muscle relaxation and potential for rough recoveries, while dexmedetomidine's effects can be reversed with atipamezole to accelerate recovery when procedures conclude.

This combination protocol has extensive history in reptile medicine, evolving from earlier ketamine-medetomidine protocols as dexmedetomidine became available. Dexmedetomidine is the pharmacologically active dextro-enantiomer of medetomidine, providing equivalent clinical effects at approximately half the dose while potentially reducing some unwanted effects associated with the inactive levo-enantiomer. The protocol has been studied across numerous reptile species including various lizards, chelonians, and snakes, providing practitioners with reasonable confidence in expected responses when appropriate dosing and technique are employed. Decades of clinical experience have refined application of this combination across diverse clinical scenarios.

Ketamine is available as an injectable solution at concentrations suitable for various species sizes, while dexmedetomidine is formulated specifically for veterinary use at concentrations allowing precise dosing even in smaller patients. Both agents can be combined in the same syringe immediately before administration, simplifying delivery through a single injection. The controlled substance status of ketamine necessitates appropriate record-keeping and secure storage, while dexmedetomidine does not carry controlled substance restrictions. Both medications maintain stability under standard storage conditions and retain efficacy when properly handled.

Clinical application of ketamine-dexmedetomidine in reptiles produces predictable chemical restraint with analgesia sufficient for many surgical and diagnostic procedures when administered at appropriate doses with attention to temperature-dependent pharmacokinetics. The availability of atipamezole as a specific antagonist for dexmedetomidine provides significant advantages by allowing partial reversal of the combination's effects, potentially shortening recovery times compared to protocols without reversible components. This reversibility has made ketamine-dexmedetomidine particularly valuable when shorter recovery is desirable or when emergency reversal capability provides important safety margins.

Ketamine-dexmedetomidine serves as an effective protocol for surgical anesthesia in reptiles undergoing procedures of short to moderate duration that do not exceed the practical limits of injectable anesthesia. Minor surgical procedures including abscess drainage and debridement, small mass removal, wound repair, laceration closure, and biopsy collection can often be accomplished within the anesthesia window provided by this combination. The analgesia contributed by both ketamine's NMDA antagonism and dexmedetomidine's alpha-2 mediated effects provides pain control during surgical manipulation. For longer procedures, ketamine-dexmedetomidine provides excellent induction conditions prior to transition to inhalant anesthetic maintenance.

Induction of anesthesia prior to inhalant maintenance represents a major application of ketamine-dexmedetomidine protocols in reptile practice. The injectable combination produces rapid onset of chemical restraint that facilitates safe handling for endotracheal intubation and connection to anesthetic breathing circuits. This approach offers substantial advantages over mask or chamber induction with inhalants alone, particularly in species prone to breath-holding or in aggressive and defensive animals where physical restraint during inhalant induction would be dangerous. Following ketamine-dexmedetomidine induction, anesthesia is smoothly maintained with isoflurane or sevoflurane, and dexmedetomidine reversal at procedure conclusion may hasten recovery.

Lizard species represent a substantial proportion of ketamine-dexmedetomidine anesthesia cases across diverse body sizes and taxonomic groups. Bearded dragons commonly receive this protocol for various surgical and diagnostic procedures, demonstrating generally predictable responses when appropriate doses are administered at correct body temperatures. Small gecko species can be effectively anesthetized with careful dose calculation accounting for their diminutive body weights. Large monitor lizards, tegus, and iguanas benefit from ketamine-dexmedetomidine induction that achieves chemical restraint before attempting handling for intubation and inhalant maintenance. Chameleons require conservative dosing approaches but can be appropriately anesthetized with this combination under experienced veterinary guidance.

Chelonian species present excellent indications for ketamine-dexmedetomidine given the significant challenges of inhalant induction in animals capable of extended breath-holding. Injectable administration bypasses respiratory uptake limitations that prolong mask or chamber inductions in turtles and tortoises. Shell repair, minor surgical interventions, and diagnostic procedures requiring immobilization are efficiently accomplished with this combination providing adequate anesthesia duration for many applications. For extended procedures, injectable induction followed by inhalant maintenance offers advantages over attempting prolonged inhalant-only induction. The reversibility of dexmedetomidine provides particular value in chelonians, which often demonstrate prolonged recovery times.

Diagnostic procedures and non-surgical interventions frequently utilize ketamine-dexmedetomidine for chemical restraint and immobilization. Radiographic imaging requiring patient positioning and stillness, ultrasound examination, blood collection from challenging species, and thorough physical examination of defensive animals all benefit from the sedation this combination provides. The analgesic properties make ketamine-dexmedetomidine suitable for mildly painful procedures including venipuncture from challenging sites. Wildlife capture situations and field procedures where portable inhalant equipment is impractical may necessitate injectable protocols, with ketamine-dexmedetomidine providing reliable chemical restraint under these circumstances.

Administration of ketamine-dexmedetomidine in reptiles requires veterinary expertise and occurs under direct supervision of qualified practitioners experienced in reptile medicine and anesthesiology. Specific doses must be determined by the attending veterinarian based on comprehensive assessment including species identification, accurate body weight measurement, current health status, planned procedure type and duration, and critically the patient's body temperature at administration. The following information describes general principles for educational purposes and should never substitute for individualized veterinary guidance during anesthetic procedures.

Temperature exerts profound influence over ketamine-dexmedetomidine pharmacokinetics in reptiles, dramatically affecting onset time, duration of action, and recovery characteristics. Reptiles at species-appropriate preferred optimum temperature zones demonstrate predictable drug responses with consistent timing of effects. Hypothermic reptiles experience severely prolonged drug metabolism with onset delayed and duration extended to clinically problematic degrees. Recovery in cold animals may extend many hours beyond expectations based on normothermic patients. Additionally, cold reptiles may show reduced initial response as impaired circulation delays drug distribution to target tissues. Warming patients to appropriate body temperatures before anesthetic administration is absolutely essential for predictable outcomes.

Intramuscular injection represents the standard administration route for ketamine-dexmedetomidine in reptiles and must exclusively target anterior body musculature due to the reptilian renal portal system. Venous drainage from the caudal body passes through renal circulation before entering systemic distribution, potentially altering drug pharmacokinetics and reducing bioavailability when posterior injection sites are used. Furthermore, ketamine and its metabolites filtered through renal tissue following caudal injection could theoretically increase nephrotoxicity risk. Appropriate injection sites include forelimb musculature, pectoral and shoulder muscles, and anterior epaxial muscles located in the front half of the body. Never administer intramuscular injections in hindlimbs, tail, or posterior body regions regardless of apparent convenience.

Ketamine and dexmedetomidine can be combined in a single syringe immediately before injection, simplifying administration through one injection event rather than two separate injections. The medications remain stable when combined for the brief period between mixing and injection. Injection should be performed with appropriate needle selection for the patient size and injection site, ensuring true intramuscular deposition rather than subcutaneous placement which produces less predictable absorption. Aspiration before injection confirms the needle is not within a blood vessel. Slow, steady injection reduces tissue trauma and discomfort.

Intravenous administration produces more rapid onset and allows titration to effect when venous access can be established before or during induction. Accessible veins vary by species but commonly include the jugular, cephalic, and ventral tail veins. Intravenous delivery typically produces noticeable effects within one to two minutes, substantially faster than intramuscular onset. However, establishing intravenous access in unanesthetized reptiles often requires physical restraint or preliminary sedation, making intramuscular administration more practical for initial delivery in many situations. Supplemental doses can be administered intravenously during procedures if extended anesthesia duration is required.

Recovery from ketamine-dexmedetomidine anesthesia can be significantly hastened through administration of atipamezole, the specific alpha-2 antagonist that reverses dexmedetomidine effects. Reversal eliminates the dexmedetomidine contribution to sedation and analgesia, leaving residual ketamine effects that typically dissipate over subsequent time. The timing of reversal administration depends on procedure completion and clinical judgment regarding desired recovery speed. Reversal too early in recovery may produce dysphoric or uncoordinated emergence. Without reversal, recovery from ketamine-dexmedetomidine is prolonged compared to reversed protocols or alfaxalone-based alternatives, requiring extended monitoring and thermal support.

Cardiovascular effects represent significant expected consequences of ketamine-dexmedetomidine administration that require monitoring and potential management. Dexmedetomidine produces pronounced bradycardia through central sympatholytic effects that reduce heart rate substantially below baseline values. Blood pressure changes are complex, with initial peripheral vasoconstriction potentially producing transient hypertension followed by maintained hypotension in many patients. Ketamine's sympathomimetic properties partially offset dexmedetomidine's cardiovascular depression, but the combination typically produces net bradycardia and variable blood pressure effects. Patients with pre-existing cardiac disease or cardiovascular compromise may poorly tolerate these hemodynamic changes and require more intensive monitoring or alternative protocols.

Respiratory depression occurs with ketamine-dexmedetomidine and may be more pronounced than with some alternative anesthetic combinations. Both agents contribute to reduced respiratory rate and depth in a dose-dependent manner. While ketamine generally preserves respiratory reflexes better than some other anesthetics, the combination with dexmedetomidine produces clinically significant respiratory depression in many patients. Reptiles' inherent apnea tolerance provides some margin of safety, but prolonged inadequate ventilation eventually produces hypoxia and hypercapnia with adverse consequences. Supplemental oxygen and readiness for assisted ventilation are prudent precautions during ketamine-dexmedetomidine anesthesia.

Temperature-dependent effects profoundly influence ketamine-dexmedetomidine anesthesia and represent a critical concern in reptilian patients. Hypothermic reptiles experience markedly prolonged drug metabolism with duration of action extending far beyond normothermic expectations. Recovery times measured in many hours rather than the typical timeframe occur in inadequately warmed patients. The extended anesthetic duration increases vulnerability to complications including prolonged respiratory depression, hypoglycemia, and secondary hypothermia. Conversely, failure to maintain appropriate temperatures during recovery delays return to normal function. Temperature management throughout the perianesthetic period is non-negotiable for safe ketamine-dexmedetomidine use.

Prolonged and potentially rough recovery represents a recognized disadvantage of ketamine-based protocols compared to some alternatives. Without dexmedetomidine reversal, recovery from ketamine-dexmedetomidine may extend several hours in appropriately warmed patients and much longer in cold animals. The dissociative state during recovery may produce apparent awareness without purposeful movement, which can concern owners and caregivers. Some patients demonstrate muscle rigidity, paddling movements, or apparent hallucinations during emergence. Administration of atipamezole accelerates recovery by reversing dexmedetomidine but may produce uncoordinated or excitable emergence as sedation is removed while ketamine effects persist.

Local tissue effects from intramuscular injection may include pain at the injection site and local irritation affecting subsequent mobility. Proper injection technique with appropriate needle selection minimizes tissue trauma. Inadvertent subcutaneous injection rather than true intramuscular placement may prolong absorption and produce inconsistent effects. Injection site reactions severe enough to produce lasting problems are uncommon with proper technique. Any unexpected reactions during anesthesia or prolonged abnormalities during recovery warrant veterinary assessment and appropriate intervention.

Significant cardiovascular disease represents a major contraindication for ketamine-dexmedetomidine due to the substantial hemodynamic effects this combination produces. The pronounced bradycardia induced by dexmedetomidine may be poorly tolerated by patients with underlying cardiac pathology, bradyarrhythmias, or conduction abnormalities. Patients with severe dehydration and resultant hypovolemia may not tolerate the cardiovascular depression and blood pressure effects of this combination. Animals in shock or with circulatory collapse are inappropriate candidates for ketamine-dexmedetomidine. Alternative anesthetic protocols with less cardiovascular impact should be considered for patients with known or suspected cardiac compromise.

Severe hepatic or renal dysfunction represents a relative contraindication given the metabolic and excretory pathways for these medications. Ketamine undergoes hepatic metabolism, and patients with significant liver disease may demonstrate prolonged duration of action and delayed recovery. Renal excretion contributes to elimination of both ketamine and dexmedetomidine metabolites, meaning renal impairment could extend drug effects. Reptiles with documented hepatic lipidosis, infectious hepatitis, or chronic kidney disease require careful consideration of anesthetic options. While reversal of dexmedetomidine with atipamezole provides some safety margin, prolonged ketamine effects cannot be antagonized and must be allowed to dissipate through metabolism and excretion.

Severe hypothermia or inability to maintain appropriate body temperature during the anesthetic period absolutely contraindicates elective use of ketamine-dexmedetomidine. Drug metabolism is dramatically impaired in cold reptiles, producing unpredictable and markedly prolonged duration of action. Recovery times in hypothermic patients may extend to twelve hours or longer, creating significant welfare concerns and logistical challenges. Facilities lacking appropriate thermal support equipment should not attempt ketamine-dexmedetomidine anesthesia. Emergency situations may necessitate proceeding despite suboptimal conditions, but the veterinarian must anticipate severely extended recovery and potential complications associated with temperature-dependent pharmacokinetic alterations.

Known hypersensitivity to ketamine, dexmedetomidine, or related compounds contraindicates use of this combination. Previous adverse reactions to alpha-2 agonists would preclude dexmedetomidine use, while ketamine hypersensitivity would eliminate the dissociative component. Patients with history of seizures may warrant caution with ketamine due to its potential to lower seizure threshold in some species, though this concern is extrapolated from other animal groups. Glaucoma represents a potential contraindication based on ketamine's effects on intraocular pressure observed in mammals. The attending veterinarian must evaluate patient history and current status to identify contraindications specific to individual cases.

Ketamine and dexmedetomidine demonstrate significant beneficial interaction when combined, with dexmedetomidine addressing major limitations of ketamine as a sole agent. Ketamine alone produces dissociative anesthesia with poor muscle relaxation and potentially rough recoveries characterized by muscle rigidity and emergence delirium. Dexmedetomidine provides the muscle relaxation, additional sedation, and analgesic contribution that transforms ketamine into a more complete anesthetic combination. The synergy between these agents allows reduced doses of each compared to what would be required individually, potentially improving safety margins. This beneficial interaction is the fundamental basis for the combination protocol.

Atipamezole represents the most clinically important drug interaction, providing specific antagonism of dexmedetomidine effects that enables partial reversal of ketamine-dexmedetomidine anesthesia. Administration of atipamezole competitively displaces dexmedetomidine from alpha-2 adrenergic receptors, eliminating the alpha-2 agonist contribution to sedation, analgesia, and cardiovascular effects. Reversal hastens recovery and may be valuable when procedures conclude earlier than expected or when prolonged recovery poses concerns. However, reversal leaves residual ketamine effects without the smoothing influence of dexmedetomidine, potentially producing dysphoric or uncoordinated emergence. Timing and appropriateness of reversal requires clinical judgment by the supervising veterinarian.

Other central nervous system depressants interact additively with ketamine-dexmedetomidine, potentially producing excessive sedation or dangerously deep anesthesia. Opioid analgesics contribute additional respiratory depression and sedation when combined with this protocol. Benzodiazepines enhance central nervous system depression through different mechanisms. Other alpha-2 agonists should not be administered concurrently due to cumulative effects. Phenothiazine tranquilizers add hypotensive effects that may compound dexmedetomidine's cardiovascular depression. While multimodal combinations may be deliberately employed by experienced practitioners for specific purposes, awareness of additive interactions guides appropriate monitoring intensity and dose adjustments.

Nephrotoxic medications warrant careful consideration when ketamine-dexmedetomidine anesthesia is planned. Aminoglycoside antibiotics including amikacin and gentamicin carry nephrotoxicity risks that could be exacerbated if anesthesia-associated hypotension or vasoconstriction compromises renal perfusion. Non-steroidal anti-inflammatory drugs pose similar renal concerns during periods of altered renal blood flow. The renal portal system consideration for injection site selection becomes particularly relevant when nephrotoxic drugs are part of the treatment plan, as ketamine injected caudally would transit renal tissue before systemic distribution. Ensuring adequate hydration and using appropriate injection sites helps protect renal function. Timing of nephrotoxic drug administration relative to anesthesia should be coordinated with the veterinarian.

Temperature management constitutes the paramount precaution for ketamine-dexmedetomidine anesthesia in reptiles and demands meticulous attention from pre-induction through complete recovery. Patients must achieve species-appropriate preferred optimum temperature zones before drug administration to ensure predictable onset and duration of effects. Supplemental heating through circulating warm water blankets, forced air warming systems, or carefully regulated radiant heat maintains body temperature throughout procedures. Continuous temperature monitoring via cloacal, esophageal, or surface probes guides adjustment of thermal support. Recovery areas must maintain appropriate temperatures to prevent secondary hypothermia and support timely return to normal function. The prolonged duration characteristic of ketamine-dexmedetomidine makes temperature-related complications particularly problematic with this protocol.

Intramuscular injection site selection requires strict adherence to anterior body placement due to the reptilian renal portal system and the specific concerns regarding ketamine and renal tissue. All intramuscular injections must target forelimb muscles, shoulder and pectoral musculature, or anterior epaxial muscles in the front half of the body. Posterior injection sites including hindlimbs, tail, and caudal body musculature are absolutely contraindicated regardless of convenience considerations. The first-pass renal exposure following caudal injection could theoretically increase any nephrotoxic potential while simultaneously reducing systemic drug availability. This anterior injection requirement applies universally across reptile species receiving ketamine-dexmedetomidine.

Cardiovascular monitoring is essential during ketamine-dexmedetomidine anesthesia given the significant hemodynamic effects, particularly the pronounced bradycardia induced by dexmedetomidine. Heart rate assessment via Doppler flow detection, electrocardiography where available, or direct visualization in species with translucent ventral surfaces enables detection of excessive bradycardia. Severe bradycardia may require intervention with anticholinergic agents or, in extreme cases, partial reversal with atipamezole. Blood pressure monitoring, while technically challenging, provides valuable perfusion information. Fluid therapy supports cardiovascular function and maintains tissue perfusion during extended procedures.

Controlled substance regulations governing ketamine mandate specific handling, storage, and record-keeping practices. Ketamine must be maintained in secure storage preventing unauthorized access as required by Schedule III controlled substance regulations. Accurate logs documenting acquisition, use, and disposal satisfy regulatory requirements and facilitate accountability. Personnel authorized to handle controlled substances should administer ketamine, and appropriate documentation must accompany each use. Disposal of unused ketamine must comply with controlled substance destruction requirements including appropriate witnessing and documentation.

Recovery management requires extended commitment when using ketamine-dexmedetomidine compared to shorter-acting alternatives. Without atipamezole reversal, recovery may extend several hours in appropriately warmed patients. Continuous monitoring during the prolonged recovery period detects complications including respiratory depression, temperature dysregulation, and emergence abnormalities. Patients must be maintained in thermally appropriate, safe environments that prevent injury during the uncoordinated phases of recovery. Staff availability for extended monitoring should be confirmed before selecting this protocol for late-day procedures. Communication with clients regarding expected recovery duration sets appropriate expectations.

Ketamine storage and handling must comply with Schedule III controlled substance regulations, which mandate secure storage in locked cabinets or safes preventing unauthorized access. Record-keeping requirements include documentation of acquisition with supplier information, accurate logs of each use with patient identification and amount administered, and accounting for all product received versus used plus any waste. Regular inventory reconciliation identifies discrepancies that must be investigated and documented. Multi-dose vials should be handled with appropriate aseptic technique and dated when first broached, with discard occurring according to facility protocols or manufacturer guidance. Storage at controlled room temperature as specified by the manufacturer maintains product stability throughout the labeled shelf life.

Dexmedetomidine, while not a controlled substance, requires appropriate pharmaceutical storage and handling practices. Storage at manufacturer-specified conditions, typically controlled room temperature protected from light and temperature extremes, maintains stability and potency. Multi-dose formulations should be handled aseptically and dated when opened, with discard occurring according to labeling or facility protocols. While security requirements are less stringent than for ketamine, appropriate inventory management and access controls consistent with general pharmaceutical handling standards should be maintained. The concentrated formulation requires careful dose calculation and measurement to prevent dosing errors.

Disposal of ketamine requires compliance with controlled substance destruction regulations that specify acceptable methods, documentation requirements, and witnessing provisions. Unused portions from single-use vials and expired product must be destroyed through approved methods rather than discarded in general waste. Many veterinary practices utilize reverse distribution services or DEA-authorized destruction methods for controlled substance disposal. Documentation of destruction including date, amount, method, and witness signatures satisfies regulatory requirements. Dexmedetomidine disposal follows standard pharmaceutical waste guidelines applicable to the practice location. Sharps and injection supplies require appropriate disposal in designated sharps containers regardless of which medications they contacted.

Lizard species demonstrate variable responses to ketamine-dexmedetomidine that reflect differences in metabolism, size, and individual sensitivity. Bearded dragons represent one of the most frequently anesthetized lizard species with this protocol, generally showing predictable induction and recovery when appropriate doses are administered at correct body temperatures. Small gecko species including leopard geckos require precise dose calculation due to their diminutive body weights, with the concentrated dexmedetomidine formulation facilitating accurate small-volume dosing. Chameleons demonstrate recognized sensitivity to anesthetic agents and typically require conservative dosing with this combination under experienced veterinary guidance. Large monitors, tegus, and iguanas often receive ketamine-dexmedetomidine for induction given the handling challenges these powerful species present, with transition to inhalant maintenance for extended procedures.

Chelonian patients including aquatic turtles and terrestrial tortoises commonly receive ketamine-dexmedetomidine for procedures where injectable anesthesia offers advantages over challenging inhalant induction. The ability to bypass breath-holding behaviors that extend inhalant induction times makes injectable protocols particularly valuable in chelonians. Shell coverage affects injection site access, with forelimb musculature reached through the axillary region being commonly utilized. Larger tortoises may receive injections into shoulder musculature accessible when the head is withdrawn. Recovery times in chelonians are often prolonged compared to lizards under comparable conditions, making dexmedetomidine reversal with atipamezole particularly valuable in these species. Temperature management requires particular attention in chelonians prone to heat loss.

Snake species can be anesthetized with ketamine-dexmedetomidine, with anatomical considerations affecting administration technique. The absence of limbs requires injection into anterior epaxial musculature, typically in the cranial one-third of body length to comply with anterior injection site requirements. Achieving true intramuscular placement in cylindrical-bodied snakes requires attention to injection depth and angle. Common pet species including ball pythons, corn snakes, and various boas demonstrate generally predictable responses when appropriate technique is employed. Large constrictor species may receive ketamine-dexmedetomidine to achieve safe handling conditions before intubation for inhalant maintenance during extended procedures.

Crocodilian species require specialized expertise and extensive safety protocols for any anesthetic procedure, with ketamine-dexmedetomidine commonly employed given the impracticality of physical restraint for inhalant induction in these dangerous animals. Remote injection techniques or pole syringes may be necessary for initial drug delivery in larger individuals. Species-specific dosing information is more limited than for commonly kept reptiles, requiring conservative approaches and extrapolation from available data. The reversibility of dexmedetomidine provides particular value in crocodilians where recovery prediction is challenging. Only facilities with appropriate crocodilian experience, safety infrastructure, and emergency protocols should attempt anesthetic procedures in these animals.

Ketamine-medetomidine represents the closely related predecessor protocol using racemic medetomidine rather than the pure dexmedetomidine enantiomer. Medetomidine contains equal parts dexmedetomidine and the pharmacologically inactive levo-medetomidine, requiring approximately twice the volume for equivalent alpha-2 agonist effect. Clinical outcomes are comparable when doses are appropriately adjusted. Some practitioners prefer medetomidine based on familiarity and cost considerations, while others favor dexmedetomidine's improved enantiomeric purity. Atipamezole reverses both medetomidine and dexmedetomidine with equivalent efficacy. Selection between these options often reflects product availability, practitioner experience, and economic factors rather than significant clinical differences.

Alfaxalone-based protocols represent the primary alternative to ketamine-alpha-2 combinations for injectable reptile anesthesia. Alfaxalone with or without midazolam produces generally smoother induction and recovery compared to ketamine combinations, with shorter duration of action that may be advantageous for brief procedures but limiting for longer interventions. The lack of controlled substance restrictions for alfaxalone (midazolam is Schedule IV) simplifies regulatory compliance compared to ketamine protocols. Recovery from alfaxalone-midazolam is typically faster than unreversed ketamine-dexmedetomidine, though reversal of the dexmedetomidine component with atipamezole narrows this difference. Cost comparison varies by market, but alfaxalone is generally more expensive than ketamine on a per-dose basis.

Inhalant anesthetics including isoflurane and sevoflurane complement ketamine-dexmedetomidine for procedures requiring extended anesthesia duration. Injectable induction followed by inhalant maintenance combines handling advantages of chemical restraint with the controllable depth and unlimited duration offered by inhalant agents. For extended surgical procedures, transition from ketamine-dexmedetomidine induction to inhalant maintenance represents standard practice. Dexmedetomidine reversal with atipamezole at procedure conclusion may accelerate recovery even when inhalants were used for maintenance, as residual alpha-2 agonist effects would otherwise contribute to emergence time. This flexible combination approach allows tailoring of anesthetic protocols to specific case requirements.